Portage Biotech Announces Board Changes Portage Biotech (PRTG) has released an update. Portage Biotech Inc. has announced the immediate resignations of board members Mark J. Simon, Linda …
Immuno-oncology company Portage Biotech to evaluate strategic alternatives The company also plans to implement additional measures. This decision comes as the company seeks to extend its cash runway available and reassess its capital raising options in The post Immuno-oncology company Portage Biotech to evaluate strategic alternatives appeared first on Pharmaceutical Business review .
Portage Biotech Explores Strategic Alternatives Portage Biotech (PRTG) has released an update. Portage Biotech Inc. is reassessing its strategic options, including potential asset sales, mergers,…
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares Company generated approximately $2.8M of non-dilutive funding to extend cash runway Company generated approximately $2.8M of non-dilutive funding to extend cash runway
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development
Portage Biotech to halt iNKT drug program, cut workforce Portage Biotech (PRTG) said that it was halting its iNKT clinical program and would be cutting its workforce in order to focus on its adenosine clinical drug ca
Portage Biotech Reports Business and Strategic Update WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced the outcome from the company's comprehensive review of its pipeline in the context of the current capital raising market conditions.